Jan 9, 2024
Moonwalk steps out with $57m for epigenetic reprogramming platform
Posted by Cecile G. Tamura in categories: biotech/medical, genetics
“Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible.”
Company co-founded by Alex Aravanis and Feng Zhang targets epigenetic code to reprogram cells to a healthy state.